CYP 2021 - The year ahead, page-295

BioScience Managers put the interview on their website as well:
https://biosciencemanagers.com/bioscience-managers-this-biotech-focused-fund-explains-why-it-invested-15m-in-these-2-asx-stocks/


What I like:


https://biosciencemanagers.com/about-us/


Just a few things that have happened over the past few months:

• Loans repaid well before the due date, including a blocktrade very close to a 52 week low
• Dr Darryl Maher joined the board
• Streamline the Securities Dealing Policy with the likes of CSL
• Dr Paul Wotton stepping down as Chairman
• Dr Geoff Brooke appointed new Chairman
• Change of business strategy (running our own P2 trials - plural - since the initial strategy to complete one P1 trial and partner everything else going forward has proven to be too ambitious for a world-first cutting edge technology)
• A Capital Raise that finally allowed existing (long term) shareholders to participate in a reasonable and fair way (in my opinion)

But what do they (BioScience) know...


https://biosciencemanagers.com/about-us/


They can't compete with "HotCopper's Finest"


#handson